跳至主要内容
临床试验/CTRI/2024/02/062982
CTRI/2024/02/062982尚未招募3 期

Efficacy and safety of daily oral steroid and cyclophosphamide versus cyclical steroid and cyclophosphamide in adult nephrotic syndrome patients with membranous nephropathy :A Randomized Controlled Trial. - nil

Department of Nephrology0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
3 期
状态
尚未招募

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • 1.Age 18 to 80 years with nephrotic syndrome
  • 2.Membranous nephropathy diagnosed by renal biopsy
  • 3.Patients classified as moderate risk, high risk or very risk as defined by KDIGO 2021 guidelines for membranous nephropathy
  • 4.Estimated GFR more than 30 ml/min/1.73m2 of body surface area, as calculated using CKD-EPI formula
  • 5.In females, has to be practicing medically approved method of contraception, or surgically sterile or post-menopausal

排除标准

  • 1.Secondary causes of membranous nephropathy will be excluded (SLE, medications like NSAIDs, COX-2 inhibitors, malignancy)
  • 2.Active underlying infection, including but not limited to hepatitis B, hepatitis C, HIV
  • 3.Pregnant or breast-feeding women
  • 4.Allergy or hypersensitivity to cyclophosphamide (oral or intravenous)
  • 5.Immunosuppressant intake in the 6 months prior to enrolment

研究者

相似试验